Thrombocytopenia News and Research

RSS

Thrombocytopenia is a condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.

New preclinical study shows promise for treating necrotizing enterocolitis

Necrotizing enterocolitis (NEC), a rare inflammatory bowel disease, primarily affects premature infants and is a leading cause of death in the smallest and sickest of these patients.

6 May 2020

Majority of patients with mantle cell lymphoma may benefit from CAR T-cell therapy KTE-X19

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

1 Apr 2020

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Lessons learned from three Singapore COVID-19 clusters

A study published in the journal The Lancet in March 2020 reports on three clusters of COVID-19 that happened in Singapore in February 2020. The first was because of a tour group, the second a company conference, and the third a church gathering.

17 Mar 2020

New antibody-drug conjugate shows promising activity in salivary gland tumors

The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology.

7 Jan 2020

UTHealth scientist receives NIH grants for liver injury research

Tiny solutions are being sought for big liver problems by a scientist at McGovern Medical School at The University of Texas Health Science Center at Houston.

21 Dec 2019

Inhibition of a single enzyme may reduce heparin-induced thrombocytopenia

Heparin is widely used as an anticoagulant, but evokes in some patients a potentially life-threatening condition called HIT. Clinical scientists at Ludwig-Maximilians-Universitaet in Munich have now shown that inhibition of a single enzyme may markedly reduce this risk.

21 Dec 2019

New combination therapy can lead to durable responses in patients with multiple myeloma

An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

17 Dec 2019

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.

28 Sep 2019

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy did not increase myocardial infarction or stent thrombosis in high bleeding risk patients treated with a contemporary drug-eluting stent.

27 Sep 2019

Researchers find synergistic connection between two deadly blood-clotting diseases

Two rare but potentially deadly blood-clotting diseases, namely thrombotic thrombocytopenic purpura, or TTP, and hemolytic uremic syndrome, or HUS, show similar pathologies -- a multitude of painful blockages in small blood vessels that cause varying degrees of organ injury throughout the body. However, the two disorders have distinct biological mechanisms.

8 Sep 2019

DNA vaccine for tick-borne disease ‘SFTS’ confers protection against lethal infection in ferrets

A KAIST research team reported the development of a DNA vaccine for Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) which completely protects against lethal infection in ferrets.

29 Aug 2019

FDA approves new drug to treat patients with myelofibrosis

Today, the U.S. Food and Drug Administration approved Inrebic (fedratinib) capsules to treat adult patients with certain types of myelofibrosis.

18 Aug 2019

Researchers test new drug to treat patients with chylomicronemia syndrome

People with familial chylomicronemia syndrome are born with a genetic mutation that means they can't produce an enzyme called lipoprotein lipase.

9 Aug 2019

$FDA grants accelerated approval to new treatment for refractory multiple myeloma$

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

3 Jul 2019

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

10 Jun 2019

FDA extends indication of metastatic breast cancer treatment to include male patients

The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

5 Apr 2019